Perspective
Renal Cell Carcinoma: Diagnostic and Immunotherapeutic Value of CD248
Author(s): Alice Brown*
The most frequent kind of cancer in the urinary system is Renal Cell Carcinoma (RCC). The survival outcome for advanced RCC remains unsatisfactory despite notable advancements in therapy. Finding novel biomarkers to help with early diagnosis and screen patients for immunotherapy sensitivity would be advantageous. A promising possibility that needs to be looked at is CD248. The dataset from the Cancer Genome Atlas (TCGA) and a clinical sample were used to compare the expression of CD248 in normal and malignant tissues. A CD248-based prognostic signature was created using univariate and multivariate Cox regression analysis to find independent predictive variables. The relationship between the current signature, immune cells that have infiltrated the tumor, the Tumor Mutation Burden (TMB), and immunomodulatory chemicals were assessed. To investigate the underlying mechanism of CD248 in R.. Read More»
DOI:
0
